Drug Trial Radar · NCT07102511
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Jul 31, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins. The main question\[s\] it aims to answer are: How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety concerns? Researchers will compare Lerochol to placebo (inert or dummy injection solution). Participants will visit the clinic every month for months and be asked to fast overnight, but allowed to drink water, before clinic visits. Undergo physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.
Conditions
- Familial Hypercholesterolemia - Heterozygous
Interventions
lerodalcibep 300 mg Monthly SCBiological
lerodalcibep or placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Low Density Lipoprotein cholesterol at week 12Time frame: Week 12
Locations
7 sites in 6 countries. Site status is shown where the registry gives one.
Metabolic & Atherosclerosis Research Center
Cincinnati, Ohio
Lipid Clinic Hadassah Medical Center
Jerusalem, Israel
New Zealand Clinical Research
Christchurch, New Zealand
The Lipid Clinic Oslo University Hospital
Oslo, Norway
Iatros International
Bloemfontein, Free State, South Africa
Lipid Clinic Wits University
Johannesburg, Gauteng, South Africa
Ege Universitesi Tip Fakultesi
Izmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.